文献速递胸部肿瘤

非小细胞肺癌免疫治疗耐药机制与新兴策略综述

Overcoming Primary and Acquired Resistance to Immunotherapy in Non-Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies.
PubMed 文献 · J Clin Oncol · 2026-05-22

本文综述非小细胞肺癌免疫检查点抑制剂原发性和获得性耐药的机制、挑战与新兴策略。获得性耐药涉及抗原提呈受损、T细胞耗竭及肿瘤微环境重塑。克服策略包括新一代免疫检查点抑制剂、表观遗传调节剂、代谢药物、细胞免疫治疗、抗体药物偶联物及疫苗等,强调生物标志物驱动选择与合理联合。

要点

  • 获得性耐药机制涉及β2微球蛋白/HLA突变、T细胞耗竭和肿瘤微环境重塑。
  • 新兴策略包括靶向TIGIT/LAG-3、表观遗传调节剂及STK11/KEAP1相关代谢药。
  • 生物标志物驱动患者选择和合理联合是克服耐药的关键方向。

核心结论

  • 克服非小细胞肺癌对免疫检查点抑制剂的获得性耐药需要生物标志物驱动的患者选择和合理联合策略,以实现更持久和个体化的免疫治疗结局。

研究设计与样本

  • 本文为综述,总结当前对免疫检查点抑制剂耐药的理解并重点介绍正在研究的克服耐药的策略。

主要发现

  • 获得性耐药在初始应答后出现,反映肿瘤演化、免疫逃逸和代谢重编程。
  • 关键机制可能包括抗原提呈受损(β2微球蛋白、人类白细胞抗原突变)、T细胞耗竭和肿瘤微环境重塑。

临床怎么用

  • 临床可关注生物标志物驱动的患者选择,并考虑合理联合新一代免疫检查点抑制剂、表观遗传调节剂、代谢药物、细胞免疫治疗、抗体药物偶联物或疫苗等策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acquired resistance (AR) to immune checkpoint inhibitors (ICIs) remains a major obstacle to durable clinical benefit in non-small cell lung cancer (NSCLC). Emerging after initial responses, AR reflects tumor evolution, immune escape, and metabolic reprogramming. Key mechanisms may include impaired antigen presentation (β2-microglobulin, human leukocyte antigen mutations), T-cell exhaustion, and remodeling of the tumor microenvironment (TME). In this review, we summarize the current understanding of ICIs resistance and highlight therapeutic strategies under investigation to overcome it. Novel approaches include next-generation ICIs targeting TIGIT and LAG-3, epigenetic modulators (HDAC, DNMT inhibitors), and metabolic agents relevant to STK11 and KEAP1 mutations. Additional strategies aim to reprogram the TME through AXL or multikinase inhibition, tumor-treating fields, and cytokine- and/or gene-based therapies. Cellular immunotherapies (tumor-infiltrating lymphocytes, T-cell receptors, chimeric antigen receptor-T), antibody-drug conjugates, and vaccines offer complementary means to restore antitumor immunity. Advancing the field will require biomarker-driven patient selection and rational combinations to overcome AR and achieve more durable, personalized immunotherapy outcomes in NSCLC.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hidalgo-Filho CM, Santo V, Gariazzo E, et al. Overcoming Primary and Acquired Resistance to Immunotherapy in Non-Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies. J Clin Oncol. 2026. PMID: 42172565. doi:10.1200/JCO-25-03026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。